Author: admin

Tirzepatide, an injection medication already approved by the Food and Drug Administration (FDA) to treat Type 2 diabetes, is likely to receive FDA approval for another indication — weight loss — later this year, according to multiple reports.The medication from Eli Lilly has the potential to become a “blockbuster” weight-loss drug, according to reports. Yet experts caution that many patients may not be able to afford it.”Tirzepatide is currently FDA-approved for treating Type 2 diabetes, but it is being fast-tracked through the FDA to receive an indication for the treatment of obesity,” Dr. Fatima Stanford of Boston told Fox News Digital. OZEMPIC TRENDING…

Read More

The New Year is a great time to ensure that all your devices are operating on the most up-to-date software and that your privacy is being protected. With all this in mind, here’s a step-by-step guide to help you with these top priorities. CLICK TO GET KURT’S CYBERGUY NEWSLETTER WITH QUICK TIPS, TECH REVIEWS, SECURITY ALERTS AND EASY HOW-TO’S TO MAKE YOU SMARTER WINDOWS Be sure to update your Windows laptop. (CyberGuy.com)How to keep your Windows devices up-to-date Select StartClick SettingsClick Windows UpdateClick Check for Updates.HOW TO AVOID BEING DUPED BY ROBOCALLS NOW AND FOREVERIf a feature update is available for your device, it…

Read More

New research presented by neuroscientists at the University of North Carolina at Chapel Hill found young adolescents who habitually checked social media showed a distinct neurodevelopmental trajectory within the brain.Their sensitivity toward social rewards and punishments from peers heightened over time in comparison with those who engaged in moderate or low checking behaviors. The three-year study of 169 sixth- and seventh-grade students from three public middle schools in rural North Carolina was published Tuesday in the journal JAMA Pediatrics.The authors used functional magnetic resonance imaging (MRI) from recruits who were between the ages of 12 and 15. HOW TO AVOID BEING DUPED…

Read More